Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model
Open Access
- 8 June 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 908
Abstract
Background: Toxoplasma gondii (T. gondii) is one of the most prevalent parasitic zoonoses worldwide, and the host’s immunological state significantly influences its clinical manifestations, which can be potentially fatal in immunocompromised hosts. The unavailability of a vaccine, combined with the considerable toxicity of existing medications, necessitates the urgent search for new therapies or adjunctive techniques, including regenerative and immunomodulatory approaches. Hence, the present study investigated, for the first time, the therapeutic potential of syngeneic platelet rich plasma (PRP) against T. gondii ME49 strain-induced chronic toxoplasmosis in both immunocompetent and immunosuppressed mouse models. Methods: 72 albino mice were divided into two sections, immunocompetent and immunosuppressed. Each section contained six groups: healthy, model, cotrimoxazole (CTZ)-treated, PRP-treated, half-dose of both CTZ and PRP-treated, and full-dose of both CTZ and PRP-treated. Treatment efficacy was assessed via parasitological, histological, immunohistochemical, and immunological analyses. Results: PRP, especially when coadministered with the CTZ, mitigated the consequences of toxoplasmosis by significantly reducing brain cyst counts (p < 0.0001), restoring brain tissue architecture, modulating apoptotic pathways by restoring caspase-3 expression in the brain, and normalizing systemic IFN-γ, TNF-α, and IL-10 cytokine profiles. Conclusions: The findings highlight PRP as an adjunct to the reference treatment, CTZ, for controlling toxoplasmosis in both immunocompetent and immunosuppressed conditions via anti-infective, neuroprotective, and immunomodulatory activities.Keywords
Funding Information
- Deanship of Scientific Research (DSR) at King Abdulaziz University (IPP: 1255-142-2025)
This publication has 53 references indexed in Scilit:
- Promising therapeutic effects of Portulaca Oleracea loaded iron oxide nanoparticles in Toxoplasma gondii infection in miceJournal of Parasitic Diseases, 2025
- Investigating Therapeutic Potential of Beta‐Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo StudiesChemistry & Biodiversity, 2025
- Chemotherapy against Toxoplasma gondii: A bibliometric analysis of in vitro and mouse model studies (2015–2024)Biomedicine & Pharmacotherapy, 2025
- Zingiber officinale Ameliorates Acute Toxoplasmosis-Induced Pathology in MiceActa Parasitologica, 2024
- Comparative evaluation of silver nanoparticles and human platelet rich-plasma versus traditional therapy in the treatment of murine chronic toxoplasmosisJournal of Parasitic Diseases, 2024
- Combining the dual antibacterial and regenerative activities of platelet-rich plasma with β-lactams to mitigate MRSA-infected skin woundsBiomedicine & Pharmacotherapy, 2023
- The potential curative and hepatoprotective effects of platelet rich plasma on liver fibrosis in Schistosoma mansoni experimentally infected miceJournal of Parasitic Diseases, 2023
- Potential effects of alpha-pinene, a monoterpene commonly found in essential oils against Toxoplasma gondii infection; an in vitro and in vivo studyJournal of Parasitic Diseases, 2022
- Activity of isoflavone biochanin A in chronic experimental toxoplasmosis: impact on inflammationParasitology Research, 2022
- Protocol for Obtaining Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and Thrombin for Autologous UseAesthetic Plastic Surgery, 2012